Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341978 | 0.79 | CA1 (0.40) | AAK1CA1CA2CA9P4HB | |
| SCHEMBL3345456 | 0.78 | LIPG (0.43) | CA1CA2CA9P4HBF2 | |
| SCHEMBL1787159 | 0.74 | AAK1 (0.39) | AAK1CA1CA2CA9F2 | |
| SCHEMBL1787160 | 0.74 | F2 (0.36) | AAK1CA1CA2CA9P4HB | |
| SCHEMBL1789481 | 0.73 | AAK1 (0.45) | AAK1CA1CA2CA9HIF1A | |
| SCHEMBL16468001 | 0.72 | CA1 (0.43) | AAK1CA1CA2CA9P4HB | |
| SCHEMBL28895528 | 0.71 | CA1 (0.44) | AAK1CA1CA2CA9P4HB | |
| SCHEMBL4084426 | 0.69 | CA1 (0.47) | AAK1CA1CA2CA9P4HB | |
| SCHEMBL2559060 | 0.66 | LIPG (0.48) | CA1CA2CA9P4HBF2 | |
| SCHEMBL12077661 | 0.66 | CA1 (0.48) | AAK1CA1CA2CA9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | AAK1 1001/4885CA1 4423/4885CA2 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.